AKEBIA THERAPEUTICS, INC. Embedded Derivative, Gain on Embedded Derivative
AKEBIA THERAPEUTICS, INC. (AKBA) reported Embedded Derivative, Gain on Embedded Derivative of $800.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Income Statement › Other Income
us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative · last filed 2024-03-14
- AKEBIA THERAPEUTICS, INC. embedded derivative, gain on embedded derivative for the quarter ending 2022-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. embedded derivative, gain on embedded derivative for fiscal 2023 was $800.00K, a 27.27% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. embedded derivative, gain on embedded derivative for fiscal 2022 was $1.10M.
| Period end | Embedded Derivative, Gain on Embedded Derivative 3 month | Embedded Derivative, Gain on Embedded Derivative 9 month | Embedded Derivative, Gain on Embedded Derivative 12 month |
|---|---|---|---|
| 2023-12-31 | $800.00K 10-K · filed 2024-03-14 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.10M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $1.10M 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |